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Abstract Several kinases have been shown to phosphorylate tau
protein at Ser-262, an important site involved in the regulation of
the binding of tau to microtubules. In this study we compared the
phosphorylation of tau at Ser-262 by CaMKII, PhK and PKA in
vitro as determined by radioimmunoblots developed by the
monoclonal antibody 12E8 which recognizes P-Ser-262 and P-
Ser-356; and Ab-262, a polyclonal antibody which is specific to
unphosphorylated Ser-262 in tau. We found that the phosphor-
ylation at Ser-262 was several times more effective by CaMKII
than PKA or PhK. Employing rat brain extract as a source of all
brain kinases and KN-62, a specific inhibitor of CaMKII, we
found that CaMKII accounts for V45% of phosphorylation at
Ser-262. Furthermore, in rat brain slices kept metabolically
active in oxygenated artificial CSF, phosphorylation of tau at
Ser-262 was (i) increased up to 120% in the presence of
bradykinin, a CaMKII activator, and (ii) inhibited by V35% in
the presence of KN-62. Thus, CaMKII is a major tau Ser-262
kinase in mammalian brain.
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1. Introduction
In Alzheimer disease (AD) the most characteristic neuro-
pathological lesion is the accumulation of paired helical ¢la-
ments (PHFs). These ¢laments are formed of tau, a neuronal-
speci¢c microtubule-associated protein [1]. Tau plays an im-
portant role in neuronal morphogenesis, the maintenance of
axonal shape, and axonal transport through its ability to bind
and regulate microtubule structure and dynamics [2,3]. There
are six isoforms of human tau which are generated from a
single gene by alternative mRNA splicing [4]. These isoforms
di¡er from each other by the presence of three or four tandem
repeats of 31^32 amino acids and no, one or two inserts of 29
amino acids each near the N-terminal. The tubulin binding
repeats are rich in positively charged residues and are thought
to interact with the negatively charged carboxy-terminal re-
gion of tubulin exposed on the microtubule structure, result-
ing in a tau-microtubule binding [3,5].
Phosphorylation of tau greatly reduces its a⁄nity for mi-
crotubules [6^9]. Fetal tau, which is more phosphorylated
than normal tau, can promote microtubule assembly but
PHF-tau which also is abnormally hyperphosphorylated, can-
not [10^13]. Dephosphorylation of PHF-tau restores its ability
to promote the in vitro microtubule assembly and tubulin
binding, suggesting that phosphorylation plays a key role in
the regulation of binding of tau to microtubules. Fetal tau
and PHF-tau are phosphorylated at 11 common sites. Of
the additional 10 sites found only in PHF-tau, one is Ser-
262. The phosphorylation of tau at this site is believed to be
primarily responsible for decreasing the a⁄nity of tau for
microtubules [8,9]. Ser-262 is the only site located within the
microtubule binding repeats of tau. Inhibition of assembly
and or binding to microtubules is observed after tau is phos-
phorylated at Ser-262 by calcium calmodulin kinase II (CaM-
KII) [6,14], protein kinase A (PKA) [15,16], MARK110 kinase
[9,17], 100 kDa protein kinase [18,19], glycogen synthase kin-
ase 3 [20], casein kinase 1 [20] and protein kinase C [20].
Recently it has been shown that phosphorylase kinase
(PhK) can phosphorylate tau in a Ca2-dependent manner
on ¢ve sites including Ser-262 [21]. However, to date, no
studies have been reported in which the substrate a⁄nity for
this site by these three kinases have been compared quantita-
tively. In this study we have examined (i) the abilities of three
kinases, PKA, CaMKII and PhK, to phosphorylate Ser-262;
and (ii) the contribution of CaMKII in the phosphorylation
of tau at Ser-262 in brain. We found (i) that of the three
kinases investigated, CaMKII is most e¡ective in phosphoryl-
ating Ser-262; and (ii) that at least one third of all phospho-
rylation of tau at Ser-262 in brain is carried out by CaMKII.
2. Materials and methods
2.1. Reagents
The human tau clone 39 (kindly supplied by Dr. Michal Goedert,
MRC, Molecular Biology Labs, Cambridge, UK) which encodes for
tau isoform 3L, tau410 [4], was subcloned in Escherichia coli and
puri¢ed from cell extracts as described previously [22]. CaMKII was
puri¢ed from rat brain by the method of Ohmstede et al. [23]. PhK
from rabbit muscle was puri¢ed according to Cohen [24], PKA was
purchased from Sigma (St. Louis, MO). The monoclonal antibody
12E8 which recognizes tau phosphorylated at Ser-262 and or Ser356
[25] was a generous gift from Dr. Dale Schenk of Athena Neuro-
sciences (San Francisco, CA) and was used at a 1^2 Wg/ml dilution;
the rabbit antibody AbSer-262 was generated and a⁄nity puri¢ed [26]
and used 1:100 diluted in dot-blot assays; the monoclonal antibody
Tau-1 that recognizes tau unphosphorylated at Ser-195/198/199/202
[10,27,28] was a gift from Dr. Lester Binder of Northwestern Univer-
sity, Chicago, IL and was used at 1:10 000 dilution for assaying total
tau in radioimmunodot-blots pretreated with alkaline phosphatase
(226 U/ml; Sigma, St. Louis, MO) for 6 h at 37‡C. KN-62 which
speci¢cally inhibits CaMKII [29] at Ki 0.9 WM and bradykinin which
speci¢cally activates CaMKII [30] at 1 WM concentration were pur-
chased from Sigma (St. Louis, MO).
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2.2. Phosphorylation of tau410 by isolated protein kinases
Tau410 was phosphorylated at 30‡C for 20 min by di¡erent kinases
(at concentrations indicated in each experiment) in reaction mixtures,
unless otherwise indicated, containing 0.12 mg/ml tau, 5 mM MgCl2,
10 mM 2-mercaptoethanol, 0.25 mM ATP and 40 mM HEPES (pH
6.8 or 7.5) as described previously [22,31]. In addition, 40 Wg/ml calm-
odulin and 0.4 mM CaCl2 were included in reaction mixtures cata-
lyzed by CaMKII and 0.4 mM CaCl2 for PhK. Reactions were ini-
tiated by addition of [Q-32P]ATP (500^1000 cpm/pmol) and after 20
min of incubation, aliquots of the reaction mixtures were removed,
spotted on phosphocellulose ¢lter paper and processed as described
previously [32].
2.3. Phosphorylation of tau410 by brain extract
Rat brain extract was prepared by homogenizing the tissue in 1 vol-
ume of 100 mM Tris pH 8.6, 2 mM EGTA, 2 mM EDTA, 100 mM
NaF, 1 mM PMSF, 2 mM benzamidine, 1 mM Na3VO4, 2 mM DTT,
0.06% Brij-35, and a cocktail of protease inhibitors (leupeptin, apro-
tinin, pepstatin A at 5 Wg/ml each one) and centrifuged at 100 000Ug
for 30 min at 4‡C. The supernatant was used for the phosphorylation
assay in a ratio 1:30 of the reaction mixture as described above (Sec-
tion 2.2) and contained 10 WM okadaic acid. In the phosphorylation
experiments in which the CaMKII activity was to be inhibited, the
brain extract was ¢rst incubated with 10 WM of KN-62 (to inhibit
CaMKII) for 10 min at room temperature and then employed for the
phosphorylation reaction as described above (Section 2.2) for 10 min.
2.4. Phosphorylation in rat brain slices
Rats, 7^15 day old, were killed and the brains were rapidly dis-
sected and cooled in arti¢cial CSF (aCSF) containing 126 mM NaCl,
3.5 mM KCl, 1.2 mM NaH2PO4, 1.3 mM MgCl2, 2 mM CaCl2,
11 mM glucose and 25 mM NaHCO3 at pH 7.4, and washed two
times with the same bu¡er. The total brain was sliced into prisms
(300U300 Wm) using a McIlwain tissue chopper. Slices were dispersed
in 20 ml of gassed (95% O2/5% CO2) arti¢cial CSF at 37‡C, and
incubated in the presence of 1 WM bradykinin, 10 WM KN-62 or as
control 1 Wl/ml DMSO. After di¡erent periods of time slices were
removed and washed two times and homogenized in 10 volumes of
bu¡er containing 50 mM HEPES pH 7.5, 25 mM L-glycerophosphate,
10 mM BME, 10 mM NaF, 2 mM EDTA, 1 mM EGTA, 1 mM
PMSF, 1 mM benzamidine, 1 mM Na3VO4, and a cocktail of pro-
tease inhibitors (see above, Section 2.2). The homogenate was centri-
fuged 30 min at 100 000Ug. The supernatant was heat treated for
10 min at 95‡C and centrifuged again 30 min at 100 000Ug. The pellet
was discarded and the supernatant was dried in a Speed-Vac (Savant)
and resuspended in an adequate volume and applied to nitrocellulose
membrane for quanti¢cation by radioimmunoblot, as described be-
low.
2.5. Quantitation of total tau and phosphorylation at Ser-262 by
radioimmunodot-blot assay
Levels of site-speci¢c phosphorylation on tau were determined by
radioimmunodot-blot assay p [33] with two di¡erent antibodies, 12E8
and AbSer-262 [25,26]; in the same samples the total tau levels were
determined by ¢rst dephosphorylating tau on the blots with alkaline
phosphatase and then developing the blots with Tau-1 antibody (see
Section 2.1). In the incubation system [Q-32P]ATP was omitted and
after di¡erent times of incubation at 30‡C aliquots were removed and
heated for 5 min at 95‡C and centrifuged. Supernatants were diluted
and applied to a nitrocellulose membrane, dried 30 min at 30‡C and
blocked 1 h in 5% BSA Tris saline bu¡er. Then the membrane was
incubated overnight with the speci¢c primary antibody and after that
2 h with the suitable secondary antibody labeled with 125I. The poly-
clonal antibody AbSer-262 is more reactive with unphosphorylated
tau than tau phosphorylated at Ser-262 and this antibody is a useful
reagent for studying tau phosphorylation at the Ser-262 residue [26].
We used this antibody to determine the speci¢c phosphorylation at
this residue at 1:100 dilution. A computerized Fuji Bas-1500 video
imaging system was used to scan and quantify the radioimmunoblots.
At similar times other aliquots were removed from the incubation
system, mixed with 1 volume of sample bu¡er and run in a 10%
SDS polyacrylamide gel, transferred to Immobilon-P membranes
and blots developed with 12E8 antibody. The ratio of the immuno-
reactivity of 12E8:Tau-1 (dephosphorylated blots) represented the
phosphorylation of tau at Ser-262/356 per unit tau.
3. Results
3.1. Phosphorylation of tau by di¡erent amounts of kinase
To compare the phosphorylation of tau at Ser-262 by var-
ious protein kinases, equal amounts of enzyme activity of each
kinase must be used, because di¡erent enzymatic preparations
have di¡erent speci¢c activities. Hence, to determine the
amount of each kinase that can incorporate 1 mol of Q-32P
per mol of tau in 20 min we phosphorylated the same amount
of tau with increasing amounts of each kinase (Fig. 1). The
CaMKII preparation had a low speci¢c activity and we used a
dilution of 1:2 to have an incorporation of about 1 mol Q-32P/
mol of tau. PhK showed a linear incorporation up to at least
2 mol of phosphate when it was used at 1:2 dilution. PKA
preparation had a very high speci¢c activity and a dilution 1:8
was able to incorporate 1 mol of Q-32P/mol of tau410 in 20 min.
An assay without tau was used as a control to account for the
autophosphorylation of the kinases. We de¢ned 1 unit of each
kinase as the amount of kinase able to incorporate 1 mol of
Q-32P/mol of tau410 in 20 min at 30‡C. We found that 1 unit of
kinase activity corresponded to 10 Wg/ml of PKA and 500 Wg/
ml of PhK and CaMKII.
3.2. Total phosphorylation of tau by CaMKII, PKA and PhK
We determined the total 32P incorporation/phosphorylation
of tau410 by incubation in a reaction mixture containing
[Q-32P]ATP and 1 unit of CaMKII, PhK or PKA. At di¡erent
times 5 Wl aliquots from the incubation mixture were removed
and spotted on a phosphocellulose membrane as described
above. The total incorporation of 32P to tau was quantitated
and the result is presented in Fig. 2. The phosphorylation was
similar for the three kinases until 20 min of incubation at
30‡C, and another 80 min after that time PhK and PKA
incorporated V20% more phosphate in tau than CaMKII
and all the three enzyme reactivities were at a plateau. These
results show that by 20 min all of the three kinases can in-
corporate the same amount of 32P per mol of tau410, but
overall CaMKII is the least favorable of the three enzymes
for phosphorylation of tau410.
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Fig. 1. Incorporation of Q-32P in tau410 by di¡erent concentrations
of CaMKII, PhK and PKA preparations. Tau410 was separately
phosphorylated either by CaMKII (b), PhK (F) or PKA (R) at the
indicated dilutions. After 20 min at 37‡C aliquots of the reaction
mixtures were removed and Q-32P incorporation was quantitated as
described in Section 2.
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3.3. Phosphorylation of tau at Ser-262
The speci¢c phosphorylation of tau at Ser-262 was deter-
mined by using two di¡erent antibodies. The monoclonal anti-
body 12E8, which binds to tau phosphorylated at Ser-262
and/or Ser-356 [25], and the polyclonal antibody AbSer-262
which binds to tau only when it is unphosphorylated at Ser-
262 [26].
To evaluate which kinase is kinetically most favorable to
phosphorylate Ser-262 and/or Ser-356, we carried out the time
kinetics of phosphorylation of these sites by the di¡erent kin-
ases and quantitated the phosphorylation by radioimmuno-
dot-blot developed with these two antibodies (Fig. 3). Fig.
3A shows the plot of time-dependent phosphorylation of
tau410, developed by 12E8 antibody. The increase of immu-
noreactivity in the samples treated with CaMKII was several
fold higher than the samples treated with the other two kin-
ases during 20 min. Western blots of tau410 incubated at dif-
ferent times with each kinase also showed a clear increase of
immunoreactivity for 12E8 antibody in the samples treated by
CaMKII (Fig. 4). Quantitation of the same samples by im-
munodot-blots developed with AbSer-262 antibody showed a
higher decrease of immunoreactivity for the samples treated
with CaMKII than the samples treated with PKA or PhK
(Fig. 3B). Thus, like 12E8 antibody, the AbSer-262 antibody
also showed that Ser-262 is a several fold more preferable site
for phosphorylation by CaMKII than PKA or PhK.
3.4. Contribution of CaMKII in the phosphorylation of tau in
brain
To evaluate quantitatively the role of CaMKII in phos-
phorylation of tau at Ser-262 in brain tissue, we investigated
(i) the phosphorylation of tau410 in vitro using rat brain ex-
tract as a source of all kinases in the presence or absence of
KN-62, a speci¢c inhibitor of CaMKII; and (ii) the phospho-
rylation of tau at Ser-262 in the presence or absence of KN-62
(inhibitor) or bradykinin (activator) using brain slices kept
metabolically active in oxygenated aCSF.
Tau410 incubated with rat brain extract for 10 min at 32‡C
under phosphorylation conditions containing [Q-32P]ATP
showed only 18% inhibition in the presence of 10 WM KN-
62 as compared with the absence of this inhibitor used as a
control (100%). However, the speci¢c phosphorylation of tau
at Ser-262/356 during the 10 min of incubation as determined
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Fig. 3. A: Kinetics of phosphorylation of Ser-262/356 by di¡erent
kinases. Radioimmunodot-blot for tau phosphorylated separately by
CaMKII (b), PhK (F) or PKA (R), developed by 12E8 antibody
were quanti¢ed by phosphorimaging analysis, the background for
0 time was subtracted from all values. B: Kinetics of phosphoryla-
tion of Ser-262 by di¡erent kinases. Radioimmunodot-blots for tau
phosphorylated separately by CaMKII (b), PhK (F) or PKA (R)
developed by AbSer-262 were quanti¢ed by phosphorimaging analy-
sis, the value for 0 time was expressed as 500 arbitrary units.
Fig. 2. Phosphorylation of tau410 by di¡erent kinases. Tau410 was incubated either with CaMKII (500 Wg/ml), PhK (500 Wg/ml) or PKA (10 Wg/
ml). Aliquots of the reaction mixtures were removed at di¡erent times and Q-32P incorporation was quantitated. Controls without tau were sub-
tracted from all values.
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by radioimmunoblot with 12E8 antibody was inhibited by
45% in the presence of KN-62. These data suggested that
almost half of phosphorylation of tau at Ser-262 by brain
kinases is caused by CaMKII.
In brain slices incubated in aCSF in the presence of 1 WM
bradykinin to stimulate the brain CaMKII activity the 12E8
activity/unit tau (Tau-1 dephosphorylated) increased by 60%
as compared to the control (no bradykinin) in 1 h, 120% in 2 h
and then remained constant until 4 h. When the phosphoryl-
ation was studied in the presence of KN-62, the 12E8 activity
per unit of tau (Tau-1 dephosphorylated) decreased by 35% in
4 h in the brain slices. Thus, the studies in the brain slices, a
model of in vivo studies, con¢rmed that CaMKII is a major
Ser-262 kinase which is responsible for at least one third of
total Ser-262 phosphorylation in tau.
4. Discussion
Identi¢cation of the protein kinases that may phosphorylate
tau at Ser-262 is important since this site, the only one in the
tubulin binding repeat domains, is believed to play a critical
role in the binding of tau to tubulin, and consequently the
stimulation of assembly and the maintenance of microtubule
structure. The present study is the ¢rst (i) to compare the
ability of PhK to phosphorylate Ser-262 with the ability of
CaMKII and PKA to phosphorylate this site in unphospho-
rylated recombinant tau; and (ii) to show quantitatively the
contribution of CaMKII in the phosphorylation of tau at Ser-
262 in mammalian brain. Using two di¡erent phospho-de-
pendent antibodies we have found that over a 20 min period
tau phosphorylated with any of these three kinases at similar
stoichiometry of phosphate incorporated per mol of tau,
CaMKII could incorporate V4-fold more phosphate than
PKA and V10-fold more than PhK in Ser-262. These di¡er-
ences in the phosphorylation levels persist over 100 min of the
reaction, though are reduced between CaMKII and PKA due
to the non-plateauing of the PKA-induced phosphorylation,
and increased between CaMKII and PhK due to the earlier
plateauing of the PhK-induced phosphorylation. On the other
hand even when the total phosphorylation in tau by PhK was
similar or higher than CaMKII, the speci¢c phosphate incor-
poration at Ser-262, as determined by 12E8 or AbSer-262
antibodies, was very low.
In a previous study phosphorylation of Ser-262 was re-
ported in tau in which 2.1 mol of phosphate per mol of the
protein was incorporated over a period of 6 h [21]. However,
the phosphorylation and dephosphorylation are relatively rap-
id events and are in a dynamic equilibrium in the cell. Thus, it
is of considerable importance that when identifying protein
kinases that might be involved in phosphorylating a protein
the phosphorylation reaction in vitro be carried out over min-
utes and not hours. Over long periods of time kinetically un-
favorable sites become non-speci¢cally phosphorylated. Thus,
it is likely that the phosphorylation of Ser-262 by PhK in the
previous study represented low levels of phosphorylation con-
tinued over a period of 6 h [21]. In the present study we
employed the amount of kinases that incorporated 1 mol of
phosphate/mol of tau during 20 min. The substrate used in the
previous study [21] was tau441 (d4L) whereas we employed
tau410 (d3L). Singh et al. [34,35] have shown that when two
N-terminal inserts are present in tau structures (tau410), then
three repeat tau (tau410) is phosphorylated to a higher extent
than four repeat tau (tau441) by CaMKII and C-kinase, but
other kinases (CK1 and CK3) phosphorylated to the same
extent both tau isoforms. No studies have shown the di¡erent
a⁄nities of the three or four repeat tau toward PhK. It is
possible that PhK has more a⁄nity for Ser-262 in four than
three repeat tau.
Employing KN-62, a speci¢c inhibitor of CaMKII activity,
we found in studies using brain extract (in vitro) and as well
as in studies in brain slices (in vivo model) that this protein
kinase is responsible for at least one third of total Ser-262
phosphorylation of tau in rat brain. Stimulation of CaMKII
by bradykinin in rat brain slices demonstrated that the phos-
phorylation of tau at Ser-262 is more than doubled (120%).
Thus, CaMKII is likely to be a major tau Ser-262 kinase in
brain. MARK110 has been reported to in vitro phosphorylate
tau Ser-262 as a preferred substrate [9]. However, to date, the
contribution of this kinase in the phosphorylation of tau Ser-
262 in mammalian brain has not been shown.
In conclusion, the present study shows (i) that of the three
kinases examined, CaMKII is most e¡ective in the phospho-
rylation of tau at Ser-262; and (ii) that this enzyme is a major
tau Ser-262 kinase in mammalian brain. Previously, we have
observed that the phosphorylation of Ser-262 is catalyzed by
CaMKIIEC-kinaseEGSK-3VA-kinaseECK-1 [20]. The
abnormally hyperphosphorylated tau in Alzheimer disease is
phosphorylated at Ser-262 and phosphorylation at this site
inhibits tau’s biological activity in binding to microtubules.
The present study suggests that CaMKII deserves serious con-
sideration as one of the kinases involved in the disease.
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